Upstream Partners


Upstream News

Posts tagged Life Sciences
Children's Hospital spinoff

Upstream assists Children's National Medical Center in Robotic Surgery venture

Upstream Partners helped negotiate a license and structure a transaction that provided Omniboros, Inc., a robotic surgery company spun out of Children's National Health System, with a license to a large patent portfolio and additional know-how. Omniboros raised $1.5 million in funding from Great Point Ventures, a Silicon Valley-based venture capital firm.

The technology, known as the Smart Tissue Autonomous Robot, or STAR, has demonstrated the ability to conduct autonomous soft tissue surgery with a robotic device. The device has demonstrated the ability to suture live pigs and inanimate pig tissue with more precision than a human hand. Omniboros, based in Washington, DC., will continue in vivo testing throughout 2017 and 2018.

Click here to view the article.

StethAid by Ascultech Dx

Medtech startup wants to make it easier to detect a harmless heart murmur

Consider this scenario: During a routine physical, a pediatrician hears a heart murmur. Naturally, the child is referred to a cardiologist and an appointment is scheduled for a few days (or weeks) later. The parents are terrified, but put on their brave faces. When the appointment finally arrives, the cardiologist listens and soon diagnoses a Still’s murmur – completely harmless. The parents finally exhale, and a potentially life-changing problem simply evaporates.

Cardiologist Dr. Robin Doroshow and her colleague Raj Shekhar, principal investigator at the Sheikh Zayed Institute for Pediatric Surgical Innovation, founded AusculTech Dx and began working on a device that could be used by pediatricians to quickly diagnose Still’s murmurs.

Click here to view the article.

Glaukos stent for glaucoma treatment

Tiny New Device Helping Glaucoma Patients

A revolutionary new treatment for glaucoma is helping patients keep their eyesight. The Glaukos iStent, the smallest medical device approved by the FDA, is a one millimeter titanium tube that is put in the drainage channel in the eye to reduce pressure build-up and keep eye fluid flowing. Until the approval of the iStent, eye drops and laser surgery were the only treatment options, which come with problems. each of which has limitations, with repeat surgery often needed .

Upstream helped with negotiations related to a license between the physician inventor of the stent to Glaukos.

Click here to view the article.

New Spinal Fusion Rod Developed by ZIAN receives FDA Approval

New Sinu-Lok Spinal Fusion Rod Developed by MUSC Neuroscience Institute Receives FDA Approval

A uniquely curved titanium rod developed by Zucker Institute for Applied Neurosciences (ZIAN) at the Medical University of South Carolina (MUSC) to improve lumbar spinal fusion can be used in surgery after receiving approval from the U.S. Food and Drug Administration (FDA). Upstream Partners was instrumental in the creation and funding of ZIAN, writing the business plan, raising the funding and devising the unique relationship between a not-for-profit entity, ZIAN, and a for-profit technology accelerator.

Click here to view the article